Sarepta Therapeutics delivered strong financial results in Q2 2025, with total revenues increasing by 68% year-over-year to $611.1 million. This growth was primarily fueled by a significant increase in ELEVIDYS net product revenue following its expanded label approval. The company also reported GAAP net income of $196.9 million and non-GAAP net income of $215.2 million, alongside positive cash flow for the quarter.
Total revenues for Q2 2025 reached $611.1 million, a 68% increase compared to Q2 2024.
Net product revenues for ELEVIDYS increased by $160.1 million, contributing significantly to overall revenue growth.
The company achieved GAAP net income of $196.9 million and non-GAAP net income of $215.2 million.
Sarepta is on track to realize over $100 million in cost savings through the end of 2025, with a strategic restructuring expected to reduce annual expenses by approximately $400 million starting in 2026.
Sarepta Therapeutics is focused on strengthening its financial foundation, advancing its siRNA platform, and achieving key clinical milestones in 2025 and early 2026.
Analyze how earnings announcements historically affect stock price performance